Background: The reasons for, and the extent of, misuse of prescribed substitution medication as well as parallel consumption of other drugs during substitution-based therapy have still not been adequately researched in Germany. Methods: This study examines the use of substitution medication in German substitution clinics utilizing a nationwide survey with anonymised questionnaires. Results: The analysis of the 605 questionnaires showed a 30-day consumption prevalence of 8.8% with regard to misuse of substitution substances. The lack of available heroin (38%) and the lack of open spots in treatment programs (21%) were quoted as being the main reasons for the misuse of substitution medication. Conclusion: Although the misuse of substitution medications is considered an important problem, our study showed that the current misuse was prevalent only among a minority of the patients. German regulations focused on the avoidance of misuse might be partially contributing to the problem.

Keywords:
Opiate addiction, Substitution medication, Abuse, parallel consumption, Concomitant drug use, Family practice, Black-market price
1.
Langer K, Bühringer G, Rehm JT, Wittchen HU: Die Substitutionsbehandlung Opioidabhängiger: Grundlagen, Versorgungssituation und Problembereiche. Suchtmed 2011;13:202-212.
2.
Busch M, Haas S, Weigl M, Wirl C, Horvath I, Stürzlinger H: Langzeitsubstitutionsbehandlung Opioidabhängiger. 1. Aufl. Köln, DIMDI, 2007.
3.
BfArM: Bericht zum Substitutionsregister. Bundesinstitut für Arzneimittel und Medizinprodukte. 2015. http://bfarm.de.
4.
Michels II, Sander G, Stöver H: Praxis, Probleme und Perspektiven der Substitutionsbehandlung Opioidabhängiger in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2009;52:111-121.
5.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Europäischer Drogenbericht 2014: Trends und Entwicklungen. http://emcdda.europa.eu.
6.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Stand der Drogenproblematik in Europa. Jahresbericht, 2012. http://emcdda.europa.eu.
7.
Casati A, Sedefov R, Pfeiffer-Gerschel T: Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 2012;18:228-245.
8.
Lofwall MR, Walsh SL: A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med 2014;8:315-326.
9.
Reimer J: Kurzfassung der Folgestudie zur Nicht Bestimmungsgemäßen Verwendung von Substitutionsmitteln in Deutschland. Hamburg, Zentrum für Interdisziplinäre Suchtforschung (ZIS) der Universität Hamburg, 2011. http://zis-hamburg.de.
10.
Schmidt CS, Schulte B, Wickert C, Thane K, Kuhn S, Verthein U, Reimer J: Non-prescribed use of substitution medication among German drug users - prevalence, motives and availability. Int J Drug Policy 2013;24:e111-e114.
11.
Andrade PV, Carapinha L, Sampaio M, Shirley S, Rodrigues I, Silva M: Para além do espelho: a intervenção de proximidade nas toxicodependências. Revista Toxicodependências 2007;13:9-24.
12.
Alho H, Sinclair D, Vuori E, Holopainen A: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007;88:75-78.
13.
Wittchen HU, Bühringer G, Rehm J: Predictors, moderators and outcome of substitution treatments - Effekte der langfristigen Substitution Opioidabhängiger: Prädiktoren, Moderatoren und Outcome. Suchtmed 2011;13:197-300.
14.
Wittchen HU, Apelt SM, Christl B, Hagenau KA, Groß A, Klotsche J, Soyka M: Die Versorgungspraxis der Substitutionstherapie Opiatabhängiger (COBRA). Suchtmed 2004;6:80-87.
15.
Scherbaum N, Specka M: Komorbide psychische Störungen bei Opiatabhängigen. Suchttherapie 2014;15:22-28.
16.
Meller KH, Gemmer S, Schubert C, Tietje W, Weckbecker K, Winkler G: Buprenorphin/naloxon im Praxis-setting: Ergebnisse einer Patientenbefragung zur nicht bestimmungsgemäßen Awendung. Suchttherapie 2016;17:40-43.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.